



UNIVERSITY OF LEEDS

This is a repository copy of *Treatment of chronic or relapsing COVID-19 in immunodeficiency*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/180816/>

Version: Accepted Version

Article:

Brown, L-AK, Moran, E, Goodman, A et al. (19 more authors) (2021) Treatment of chronic or relapsing COVID-19 in immunodeficiency. *Journal of Allergy and Clinical Immunology*, 149 (2). pp. 557-561. ISSN 0091-6749

<https://doi.org/10.1016/j.jaci.2021.10.031>

© 2021 American Academy of Allergy, Asthma & Immunology. This manuscript version is made available under the CC-BY-NC-ND 4.0 license.

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>


Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Supplementary Figure 1



Supplementary Figure 1. Proportion of clinical episodes where patients experienced clinical improvement, reduction in fever, reduction in serum C-reactive protein concentration, reduction in oxygen requirement and discharge from hospital according to treatment received: combination therapy (remdesivir plus convalescent plasma or REGN-COV2 monoclonals; n=14), remdesivir monotherapy (n=23) or nil (n=22). N/A, not applicable. NK, not known.